GU Oncology Now

🔎 Take a look at our American Society of Clinical Oncology (ASCO) #GU25 conference coverage page to review all the latest data from the event and catch up with what you may have missed in #bladder, #prostate, and #kidney cancer research:

🔎 A phase I/II trial evaluating combination therapies for previously treated advanced #ccRCC suggests that #lenvatinib and #belzutifan provides promising antitumor activity with a manageable safety profile. 👉 Learn about the findings presented by Laurence Albiges at American Society of Clinical Oncology (ASCO) #GU25: https://buff.ly/42T2irV

❗️ Final results of CheckMate 9ER presented at American Society of Clinical Oncology (ASCO) #GU25 showed a long-term efficacy benefit of #nivolumab plus #cabozantinib over #sunitinib alone for untreated, advanced #RCC. 👉 No new safety signals were reported, supporting this combination as a standard of care for this patient population:

🔎 According to new data from CheckMate 214 presented at American Society of Clinical Oncology (ASCO) #GU25, KIM-1 serves as a useful biomarker for patients with advanced #RCC. 📈 Increased levels of baseline KIM-1 are associated with worse clinical outcomes for patients receiving nivolumab plus ipilimumab or sunitinib alone:

🚨 Presented today at American Society of Clinical Oncology (ASCO) #GU25: Updated results from COSMIC-313 showed that first-line treatment of advanced #RCC with #cabozantinib + #nivolumab + #ipilimumab continued to provide PFS and ORR benefits for patients with intermediate- or poor-risk disease:

☀️ The final day of @ASCO #GU25 starts now, with a focus on #kidneycancer and other rare malignancies. 📺 Join the Two Onc Docs - Drs. Karine Tawagi and Samantha Armstrong - to learn about the most anticipated presentations to watch today, including COSMIC-313, CheckMate 9ER, KEYMAKER-U03, and more: https://buff.ly/3CFqSlr

🔊 New research presented at American Society of Clinical Oncology (ASCO) #GU25 evaluated the clinical efficacy and safety of combining #durvalumab with intravesical gem/doce in a cohort from the ADAPT-BLADDER multi-arm study’s phase I and II expansion arms. 👉 Learn more about the combination's efficacy for #NMIBC:

🔎 New findings from the interim analysis of the RETAIN-2 trial, presented at American Society of Clinical Oncology (ASCO) #GU25, have shown a 46% pT0 rate among patients with muscle-invasive #bladdercancer undergoing cystectomy and a 78% metastasis-free bladder preservation rate in the study's active surveillance cohort:

🚨 Coming soon: Petros Grivas, Priyanka Chablani, MD/MS, Ali Raza Khaki, and Karine Tawagi discuss Dr. Chablani's survey-based study from @ASCO #GU25 on treatment sequencing after first-line #enfortumab vedotin/#pembrolizumab for locally advanced/metastatic urothelial cancer.

📈 Additional efficacy outcomes of the phase 3 CheckMate 274 trial, presented at American Society of Clinical Oncology (ASCO) #GU25, demonstrated the sustained DFS benefits of #nivolumab across all patients with #MIBC and in prior NAC subgroups: